3 results about "Fasting glucose" patented technology

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.